2,281 posters, 63 videos, 56 audios, 43 topics, 18 sessions, 6,174 authors, 2,323 institutions

RCOG World Congress 2025

June 23 - 25, 2025 | ExCeL London, UK

EP.0336

Cabergoline: A Promising Therapy for Reducing Inflammatory Markers and Pain in Endometriosis

View Poster Contact Presenter

Poster Presenter

Ritu Kushwah

Authors

Ritu Kushwah, Tarang Gupta, Tushar Sehgal, Anju Singh, Archana Kumari, Reeta Mahey, Garima Kachhawa

Affiliations

AIIMS NEW DELHI

Part of Topic

Endometriosis & uterine disorders

Cabergoline: A Promising Therapy for Reducing Inflammatory Markers and Pain in Endometriosis

Dr Ritu Kushwah1, Dr Garima Kachhawa1,Tarang Gupta1, Dr Tushar Sehgal2, Dr Anju Singh1, Dr Archana Kumari1, Dr Reeta Mahey1

1Department of Obstetrics and Gynaecology,2Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India

Introduction

●Endometriosis is an estrogendependent gynaecological condition marked by chronic pelvic pain and infertility

●It arises from the ectopic presence of endometrial tissue

●It affects 49% of adolescents withchronic pelvic pain and 10% ofall women of reproductive age (1)

●Inflammation and angiogenesis are important for endometriosis pathogenesis, supporting ectopic tissue survival through elevated inflammatory markers and promoting vascular growth essential for lesion maintenance (2)

Aims and Objectives

PRIMARY OBJECTIVES

To evaluate the effect of Cabergoline versus Dienogest on VEGF, TNF alpha, hsCRP

SECONDARY OBJECTIVES

To compare the efficacy of Cabergoline & Dienogest on reduction in pain and after 3 months of stopping the drug

To evaluate the effect of both treatments on volume of endometrioma

Materials & Method

●Prospective, open-label, randomized controlled study conducted at a tertiary care centre

●Sixty women with endometriosis meeting inclusion criteria were randomized into two equal groups

●Group I received Cabergoline 0.5 mg twice weekly, and Group II received Dienogest 2 mg daily for six months

Discussion

Standard treatment options for endometriosis include surgical excision or hormonal therapies aimed at inducing a hypoestrogenic state

Their use is limited in women desiring fertility

Cabergoline and Dienogest both showed significant reduction in serum TNF-alpha & hsCRP as well as pain measured by VAS

However, Cabergoline in addition significantly decreases serum VEGF, an angiogenic marker and also preserves menstrual cycle regularity

Conclusion

Cabergoline may be a potential new treatment for endometriosis associated pain in young women, recurrent endometriosis and those who prefer non-surgical management

Cabergoline can be a adjunct to fertility treatment in endometriosis associated infertility as it preserves ovarian & menstrual function

References

1.Nothnick W, Alali Z. Recent advances in the understanding of endometriosis: the role of inflammatory mediators in disease pathogenesis and treatment. F1000Research 2016;5)

2.Gargett C, Weston G, Rogers P. Mechanisms and regulations of endometrial angiogenesis. Reprod Med Rev. 2002 Mar;10(1):45–61